The Brazilian Association of Vaccine Clinics (ABCVAC) reported that the sector is negotiating the purchase of 5 million doses of Covaxin, the vaccine against COVID-19 manufactured by the Indian pharmaceutical Bharat Biotech. Last Saturday, the product obtained authorization for emergency use in India, but the data on its effectiveness are still unknown.
ABCVAC states that these 5 million doses should reach the Brazilian market by mid-March. However, this schedule depends on product certifications and Anvisa’s authorization for the emergency use of the vaccine in the country. The vaccine manufacturer needs to request these permissions from the National Health Surveillance Agency (Anvisa).
“This should be the first vaccine available to the Brazilian private market, through a Memorandum of Understanding signed with ABCVAC,” said the entity’s president, Geraldo Barbosa, in a statement. ABCVAC’s 200 associates, who say they represent 70% of Brazil’s national private market, will have priority in purchasing the immunizer.
According to Reuters, Anvisa said that Covaxin does not fit the continuous data submission process for vaccine registration in a statement on Sunday. The vaccine would have to undergo a clinical trial in Brazil, making ABCVAC’s negotiation much more complicated.